Octave® Receives $10 Million Grant from The Michael J. Fox Foundation to Develop and Validate  Biomarker Test for Parkinson’s Disease. Learn More

Octave at ECTRIMS 2022!

October 26-28, 2022

Amsterdam, the Netherlands

The ECTRIMS 2022 Congress may be over, but the journey has only begun.

Click below to read Octave’s recent announcements and each of the 13 posters presented at ECTRIMS!

Octave Commercially Launches a First-in-Class Precision Care Solution for Multiple Sclerosis


Octave’s Precision Care Solution delivers quantitative, objective insights to better characterize individual MS patients’ underlying biology, radiographic status, and evolving symptoms, creating a first-of-its-kind integrated and personalized paradigm of care to improve outcomes.

Read Article

Octave Presents Data from 13 Abstracts at ECTRIMS Forum 2022 Following Commercial Launch of Precision Care Solution for Multiple Sclerosis


Data demonstrates impact of Octave’s Precision Care Solution to track MS disease activity at individual patient and population levels, provide quantitative and deeper insights, and potentially guide treatment decisions.

Read Article


Wednesday, October 26 | Oral Presentation

  1. Biomarker – Serum Biomarkers of Progression by Proteomic Search in Extreme MS Phenotypes